Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1100)	7/10/2003 6:18:56 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

In addition, Solvay’s novel selective A1-adenosine antagonist SLV320 is approaching clinical trials for Acute Congestive Heart Failure. solvaypharmaceuticals.com (but it was in phase I in January)......... solvaypharmaceuticals.com

To: scaram(o)uche who wrote (1100)	7/13/2003 7:02:13 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1833

I called and left a message at 212-702-4367 for Ms. Paige. I asked if SLV320 was one of the molecules that could trigger milestone payments.

To: scaram(o)uche who wrote (1100)	7/13/2003 7:41:49 PM
From: scaram(o)uche	Respond to of 1833

And note that Solvay lists "Congestive Heart Failure and Renal Failure" as the potential indications for SLV320. Until now, we've only heard of CHF from OSI. Let's conservatively estimate $400M in sales for a GOOD drug, addressing the CHF market. I never saw guidance lower than 2% for the royalty. The first guidance that I got -- if I remember correctly -- was 4-6%. 2% would be $8M/year. 4% would be $16M/year. Again, whatever Icahn, Paige et al. want to do with Cadus, I certainly hope that shareholders will be able to retain a full interest in Cadus Technologies. So, the precise question..... is SLV320 the same as OSIC-0961370....... RESEARCH AND DEVELOPMENT PIPELINE The following table summarizes the status of our more advanced product candidates as of November 30, 2001 and identifies any related collaborator. <Table> <Caption> DISEASE AREA/PRODUCT DRUG TYPE STATUS(a) COLLABORATOR -------------------- --------- --------- ------------ <S> <C> <C> <C> Cancer Tarceva(TM) Epidermal growth factor receptor Phase III Genentech/Roche inhibitor NX211 Liposomal lurtotecan Phase II OSI-Owned(b) GS7836 Gemzar(R) analog Phase I OSI-Owned(b) CP-609,754 Farnesyl transferase inhibitor Phase I OSI-Owned CP-632 Vascular endothelial growth factor Phase I Pfizer receptor GS7904L Liposomal thymidycate Phase I OSI-Owned(b) CP-XXX HER2-neu IND Track Pfizer CP-XXX PDGFr IND Track Pfizer Respiratory/Asthma OSI-760 Adenosine A(1) receptor inhibitor IND Track OSI-Owned AVE0309 Interleukin-4 gene expression IND Track Aventis inhibitor Cholesterol Lowering HMR 1171/ Low density lipoprotein receptor IND Track Aventis AVE 9103A gene expression stimulator Congestive Heart Failure OSIC-0961370 Adenosine A(1) receptor inhibitor IND Track Solvay AVE9488 EcNOS gene expression inhibitor IND Track Aventis </Table>